Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24361372 | 0.76 | KMT2A (0.52) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL10119911 | 0.76 | FABP7 (0.45) | FABP7FABP5ALDH1A1TSHR | |
| SCHEMBL24361124 | 0.76 | KMT2A (0.51) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL13255974 | 0.75 | KMT2A (0.53) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL15080525 | 0.72 | FABP7 (0.58) | KMT2AMEN1NPC1GAAFABP7 | |
| Hydrochloric Acid SCHEMBL597886 | 0.72 | TSHR (0.51) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL24944135 | 0.72 | POLB (0.44) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL24361049 | 0.72 | ALDH1A1 (0.46) | KMT2APOLBMEN1NPC1GAA | |
| SCHEMBL14827593 | 0.72 | FABP7 (0.55) | NPC1FABP7FABP5ALDH1A1SMN1; SMN2 | |
| SCHEMBL14827596 | 0.72 | FABP7 (0.48) | KMT2AFABP7FABP5L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | KMT2A 3432/4885POLB 491/4885MEN1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.